Sanofi, GSK variant-specific COVID shot found effective against Omicron - 24 iunie 2022
Late-stage data on an experimental COVID-19 vaccine from Sanofi (FR.SAN) and GSK has showed the shot confers protection against the Omicron variant of the virus, the companies said on Friday.
In a trial involving 13,000 adults, the vaccine demonstrated an efficacy rate of 64.7% against symptomatic COVID, and 72% efficacy against infections specifically caused by the Omicron variant. When used in people who previously had COVID, the results were stronger. The vaccine generated an efficacy rate of 75.1% against symptomatic COVID and 93.2% in Omicron-confirmed symptomatic cases, the companies said.